[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-nephropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-nephropathy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,70,96,114,135,155,179,203,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053358","phase-4-naoxintong-capsule-for-diabetic-nephropathy-with-dampness-retention-pattern-a-multicenter-randomized-double-blind-placebo-controlled-trialacronymnxt-dkd-100053358",false,"NCT07698223","Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD","Evidence-Based Evaluation of Naoxintong Capsule in the Treatment of Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","NXT-DKD","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Meets the diagnostic criteria for Type 2 diabetic nephropathy, defined as:\n\n   1. Confirmed diagnosis of Type 2 diabetes mellitus; AND\n   2. At least one of the following: urinary albumin-to-creatinine ratio (UACR) \\>= 30 mg\u002Fg, or eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2, confirmed by repeat testing (interval \\>= 3 months), after excluding transient factors such as acute kidney injury, dehydration, infection, or heart failure; OR\n   3. Renal biopsy confirmed as isolated diabetic nephropathy; AND\n   4. Exclusion of other primary or secondary kidney diseases.\n3. 24-hour urinary protein excretion \\>= 0.5 g and \\\u003C 3.5 g.\n4. Estimated glomerular filtration rate (eGFR) \\>= 45 mL\u002Fmin\u002F1.73m\\^2.\n5. On a stable dose of ACE inhibitor (ACEI) or Angiotensin II receptor blocker (ARB) therapy for at least 8 weeks prior to enrollment. If SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), or GLP-1 receptor agonists are being used, the dose must have been stable for at least 4 weeks prior to enrollment and remain unchanged during the study period. Patients not currently using these agents must not initiate them during the study.\n6. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus or other types of diabetes mellitus (e.g., secondary diabetes, maturity-onset diabetes of the young).\n2. Coexisting systemic autoimmune or immune-mediated disease where the clinical assessment suggests a non-diabetic nephropathy etiology.\n3. Decline in eGFR of \\> 30% within the past 3 months.\n4. Persistent serum potassium \\> 5.5 mmol\u002FL.\n5. Diagnosis of hemorrhagic cardiovascular or cerebrovascular disease within the past 3 months.\n6. Known allergy or hypersensitivity to any component of Naoxintong Capsule or placebo; pregnant or lactating women.\n7. Participation in another drug or medical device clinical trial within the past 6 months.\n8. Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in the clinical trial (e.g., severe hepatic dysfunction, life expectancy \\\u003C 1 year).","ALL","18 Years",{"count":20,"type":21},410,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality. Despite current standard therapies including renin-angiotensin system inhibitors (ACEI\u002FARB), glycemic control, and blood pressure management, disease progression remains inadequately controlled in many patients.\n\nNaoxintong Capsule is a traditional Chinese medicine formulation composed of 16 herbal ingredients (Astragalus membranaceus, Prunus persica seed, Carthamus tinctorius, Paeonia lactiflora, Angelica sinensis, Ligusticum chuanxiong, Boswellia carterii, Commiphora myrrha, Salvia miltiorrhiza, Achyranthes bidentata, Cinnamomum cassia, Morus alba, Spatholobus suberectus, Buthus martensii, Pheretima aspergillum, and Hirudo nipponica). It has been widely used in China for cardiovascular and cerebrovascular diseases, with demonstrated effects on endothelial protection, anti-inflammation, anti-thrombosis, and plaque stabilization.\n\nThis multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Naoxintong Capsule added to standard conventional therapy in slowing the progression of diabetic nephropathy and providing cardiovascular protection. A total of 410 patients with Type 2 diabetic nephropathy will be randomized (1:1) to receive either Naoxintong Capsules (4 capsules, 3 times daily) or matching placebo, in addition to standard therapy, for 12 months. The primary outcome is the annual rate of decline in estimated glomerular filtration rate (eGFR). Secondary outcomes include changes in proteinuria, CKD stage progression, time to end-stage kidney disease, major adverse cardiovascular events, TCM syndrome scores, and quality of life measures.",[27],"Diabetic Nephropathy",[29,27,30,31,32,33],"Diabetic Kidney Disease","Naoxintong Capsule","Traditional Chinese Medicine","Dampness Retention Pattern","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-07-08",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":21},"2027-03-01",{"date":42,"type":21},"2028-12-30",{"name":44,"class":45},"Chen Xiangmei","OTHER",8,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100639573","phase-3-dapagliflozin-vs-dapagliflozin-finerenone-for-albuminuria-in-ckd-with-type-2-diabetes-100639573","NCT07598864","\"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes\"","Effect of Dapagliflozin Compared to Dapagliflozin-finerenone Combination on Albuminuria in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Randomized Controlled Trial.","Inclusion criteria:\n\nPatients aged ≥ 18 years Patients with T2 DM , as defined by the American Diabetic Association. Urinary ACR ≥ 30 mg\u002Fg and eGFR ≥ 25 ml\u002Fmin per 1.73 m2 Prior treatment with ACEIs or ARBs for more than four weeks up to the maximum tolerated dose Serum potassium ≤ 4.8 mmol\u002FL\n\nExclusion criteria\n\n* Patients with other known causes of proteinuria, e.g. UTI, fever\n* At screening visit SBP higher than 160 mmHg or DBP higher than 100 mmHg or SBP lower than 90 mmHg\n* Glycated hemoglobin (HbA1C) \\>11%\n* Known hypersensitivity to dapagliflozin or finerenone\n* Known case of Addison's disease\n* Known case of hepatic insufficiency\n* Treatment with SGLT2i (empagliflozin:62 hours, dapagliflozin:65hours) or MRAs (finerenone:10-20 hours, spironolactone:7 hours , eplerenone:15-30 hours) within their wash out periods.\n* Patients on non-dihydropyridine Calcium Chanel blockers or Glucagon-like peptide-1 (GLP-1) agonists\n* Pregnant lady or lactating mother",{"count":55,"type":21},88,[57],"PHASE3","Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline. Reducing albuminuria is a key therapeutic goal to slow disease progression. Sodium-glucose cotransporter-2 inhibitors like dapagliflozin and non-steroidal mineralocorticoid receptor antagonists such as finerenone have independently shown significant renoprotective effects. Their combined use may provide additive benefits.\n\nThis open-label randomized controlled trial will be conducted in the Department of Nephrology, Chittagong Medical College Hospital, Bangladesh, including 88 patients with CKD and T2DM. Participants will be randomized into two groups: one receiving dapagliflozin 10 mg plus finerenone 10 mg daily, and the other receiving dapagliflozin 10 mg alone for eight weeks.\n\nThe primary outcome will be the change in urinary albumin-to-creatinine ratio (UACR). Secondary outcomes include serum creatinine, estimated glomerular filtration rate (eGFR), and serum potassium. Safety and adverse events will also be monitored. Data will be analyzed using SPSS version 27.\n\nThis study aims to assess whether combination therapy is more effective than dapagliflozin alone in reducing albuminuria and may help guide treatment strategies in diabetic CKD.",[27],"2026-05-14",{"date":62,"type":38},"2026-05-20",{"date":64,"type":21},"2026-05-01",{"date":66,"type":21},"2027-05-01",{"name":68,"class":45},"Chittagong Medical College",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100629559","the-non-high-density-lipoprotein-cholesterol-non-hdl-c-to-high-density-lipoprotein-cholesterol-hdl-c-ratio-nhhr-and-its-association-with-occurrence-of-diabetic-nephropathy-in-patients-with-diabetes-mellitus-100629559","NCT07476248","The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosed cases of diabetes mellitus (Type 1 or Type 2), with or without diabetic nephropathy\n* Willingness to participate and provide informed consent\n\nExclusion Criteria:\n\n* Known non-diabetic causes of chronic kidney disease\n* Acute kidney injury\n* Chronic inflammatory or autoimmune diseases\n* Current use of medications known to significantly alter lipid metabolism (other than standard lipid-lowering therapy, if applicable)\n* End-stage renal disease patients on dialysis","80 Years",{"count":78,"type":21},84,"OBSERVATIONAL","The study aims to examine the relationship between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and CKD in patients with DM.",[27,82],"Dyslipidemia",[84,85,86],"Chronic kidney disease ( CKD )","Diabetes mellitus type 1","Diabetes mellitus type 2","2026-03-12",{"date":89,"type":38},"2026-03-17",{"date":91,"type":21},"2026-10-01",{"date":93,"type":21},"2027-12-01",{"name":95,"class":45},"Assiut University",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":102,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100606294","evaluating-the-roles-of-novel-inflammatory-markers-compared-to-mcp-1-in-type-2-diabetic-nephropathy-100606294","NCT07173686","Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy","Inclusion Criteria:\n\n* Adult aged 18-80 years, both genders.\n* clear history of T2DM\n\nExclusion Criteria:\n\n* Kidney disease caused by any other causes\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 - m2\n* Existing obvious infection\n* Acute stage of cardiovascular or cerebrovascular diseases\n* Acute complications of diabetes recently (such as diabetic ketoacidosis, et al.)\n* Associated malignant tumors\n* Hematological system, and autoimmune system diseases",{"count":103,"type":21},80,"Diabetic kidney disease (DKD) is one of the most common microvascular complications of type 2 diabetes mellitus (T2DM), affecting up to 40% of diabetic patients and accounting for the leading cause of end-stage renal disease worldwide \\[1\\]. The progression of DKD involves multiple mechanisms, including oxidative stress, endothelial dysfunction, and most importantly, chronic inflammation \\[2\\].\n\nSystemic inflammation plays a central role in renal injury by promoting glomerular and tubulointerstitial damage. the neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) has emerged as a readily accessible markers of subclinical inflammation. Elevated NLR and SII levels have been significantly associated with increased urinary albumin excretion and decreased estimated glomerular filtration rate (eGFR) in T2DM patients \\[3\\]. It was demonstrated that patients in the highest NLR tertile had a higher prevalence of DKD, independent of confounders \\[4\\].\n\nHigh-sensitivity C-reactive protein (hsCRP), is widely used to evaluate systemic inflammation. Recent studies have shown a strong association between elevated hsCRP levels and DKD development \\[5\\].Some studies provided genetic evidence supporting a causal relationship between higher hsCRP and diabetic nephropathy \\[6\\].\n\nMonocyte chemoattractant protein-1 (MCP-1) is a chemokine involved in monocyte recruitment to inflamed renal tissues. Elevated serum and urinary MCP-1 levels have been found to predict microalbuminuria and eGFR decline in T2DM patients \\[7,8\\].\n\nIdentifying these markers may help in early diagnosis, risk stratification, and monitoring progression of DKD.",[27],"2025-09-08",{"date":108,"type":38},"2025-09-15",{"date":110,"type":21},"2025-10-01",{"date":112,"type":21},"2026-11-01",{"name":95,"class":45},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":69},"100580899","the-intelligent-prevention-and-control-system-and-strategy-for-the-whole-disease-cycle-of-diabetic-nephropathy-100580899","NCT06843304","The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy","T2DM\n\nInclusion Criteria:\n\n* Age ≥18 years old, gender is not limited\n* Diagnosed with type 2 diabetes\n* A history of type 2 diabetes for more than 5 years\n* Negative proteinuria\n* Creatinine is normal\n* Good compliance, voluntarily sign informed consent\n\nExclusion Criteria:\n\n* Incomplete medical records\n* Lack of fundus microvascular examination or new imaging technology examination results data\n* Combined with autoimmune diseases and tumors\n\nType 2 diabetes patients undergoing renal biopsy\n\nInclusion Criteria:\n\n* Age ≥18 years old, gender is not limited\n* Diagnosed with type 2 diabetes\n* Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency)\n* Have undergone renal puncture biopsy and have complete renal pathological diagnosis data\n* Sign informed consent voluntarily\n\nExclusion Criteria:\n\n* Gestational diabetes mellitus, special type diabetes mellitus\n* Patients with hereditary kidney disease\n* Combined with autoimmune diseases\n* Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained\n* There were pregnancy plans in the study period",{"count":121,"type":21},2000,"Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. By integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. Utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. The project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. Ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.",[27,124],"T2DM","RECRUITING","2025-04-16",{"date":128,"type":38},"2025-04-20",{"date":130,"type":38},"2024-01-01",{"date":132,"type":21},"2027-12",{"name":134,"class":45},"Chinese PLA General Hospital",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":142,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100587402","assessement-of-the-knoweldge-attitudespractices-of-diabetic-kidney-disease-among-diabetic-patients-100587402","NCT06927921","Assessement of the Knoweldge ,Attitudes,Practices of Diabetic Kidney Disease Among Diabetic Patients","Assessemnt of the Knoweldge ,Attitudes and Practices of Diabetic Kidney Disease Among Diabetic Patients","Inclusion Criteria:\n\n* • Diabetic patients (either type 1or 2 DM ) with age above 18yrs old.\n\nExclusion Criteria:\n\n* • CKD patients due to cause other than diabetes.\n\n  * Patients who refuse participation in the study.",{"count":143,"type":21},400,"This research aims to evaluate the levels of knowledge , attitudes and practices, of diabetic kidney disease among diabetic patients.",[27],"2025-04-12",{"date":148,"type":38},"2025-04-15",{"date":150,"type":21},"2025-04",{"date":152,"type":21},"2026-05",{"name":95,"class":45},2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":163,"studyType":79,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":69},"100194055","repository-of-novel-analytes-leading-to-autoimmune-inflammatory-and-diabetic-nephropathies-renal-aid-100194055","NCT01802034","Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)","RENAL AID","Key Inclusion Criteria:\n\nAll Groups:\n\n* Males or females\n* 18 years of age and older\n* Willing and able to provide informed consent\n\nNative Biopsy Tissue Group:\n\n\\- Require an initial kidney biopsy for medical necessity\n\nNative Kidney, Non-tissue Group:\n\n* Previously had a kidney biopsy and the tissue is not stored in this biorepository; or\n* Have diabetes and kidney disease and have not had a kidney biopsy\n\nAllograft Tissue Group:\n\n\\- Have undergone a renal transplant and require a transplant biopsy for either surveillance or \"for-cause\" indications.\n\nKey Exclusion Criteria for all Groups:\n\n\\- Inability to provide informed consent.",{"count":121,"type":21},"10 Years","A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states. Cohorts will include subjects with diabetes, inflammatory\u002Fautoimmune and transplant related renal conditions. Additionally, the repository will have the capacity to store biospecimens and electronic data in control subjects without established renal disease. This initiative will provide an opportunity to compare data from various disease states and controls with the objective of determining clinical and biological factors that predict disease progression, response to therapy and identify discriminating noninvasive clinical and biological features that predict renal biopsy findings.",[166,167,27,168,169],"Kidney Diseases","Kidney Failure, Chronic","Lupus Nephritis","Glomerulonephritis, IGA","2025-04-01",{"date":172,"type":38},"2025-04-04",{"date":174,"type":4},"2013-02",{"date":176,"type":21},"2028-08",{"name":178,"class":45},"The Rogosin Institute",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":186,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":69},"100574558","raman-spectroscopy-diagnosis-of-kidney-diseases-100574558","NCT06760845","Raman Spectroscopy Diagnosis of Kidney Diseases","Research on Raman Spectroscopy Detection Technology in Kidney Disease Diagnosis","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. Patients diagnosed with IgA nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy;\n3. Patients who have not received hormone and\u002For immunosup therapy before the renal biopsy;\n\nExclusion Criteria:\n\n1. Presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),\u002Finfections (viral hepatitis), drugs or toxins, etc.;\n2. Severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09\u002FL);\n3. Severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias;\n4. Infect diseases: active phase of various types of hepatitis, AIDS, syphilis, etc.;\n5. Evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor;\n6. Patients with incomplete data or missed diagnosis.",true,{"count":188,"type":21},200,"This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis the Nephrology Department of Qianfoshan Hospital in Shandong Province, through renal biopsy. These samples will be scanned using a Raman spect to obtain Raman spectral data. The scattering peaks in the Raman spectra will be analyzed using Origin software for Gaussian curve fitting. The position of the peaks will used to query relevant literature to identify the corresponding chemical bonds and confirm the presence of compounds.\n\nThe intensity and area of the chemical substance peaks in the Raman will be calculated and used to plot calibration curves, thereby establishing a quantitative analysis equation. This equation will be used to accurately calculate the concentration of each analyte in serum and urine samples. Based on the average concentration data for each patient group, multivariate analysis methods, such as principal component analysis (PCA) and Mahalanis distance discriminant model, will be used to classify and predict the disease types.\n\nThe preliminary data for this study comes from the Nephrology Department ofianfoshan Hospital, where different types of glomerular diseases have been pathologically classified using tools such as light microscopy, electron microscopy, and immunoforescence microscopy. By combining Raman spectroscopy technology and statistical analysis, this study aims to establish a non-invasive and efficient diagnostic tool to assist in the of kidney diseases and predict treatment outcomes.",[191,192,27,193],"IgA Nephropathy (IgAN)","Membranous Nephropathy","Focal Segmental Glomerulosclerosis (FSGS)","2025-01-06",{"date":196,"type":38},"2025-01-07",{"date":198,"type":38},"2021-02-01",{"date":200,"type":21},"2025-07",{"name":202,"class":45},"Zunsong Wang",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":69},"100566899","a-cohort-study-on-the-efficacy-of-bariatric-surgery-for-rapidly-progressing-diabetic-nephropathy-100566899","NCT06661174","A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy","EBSDKD","Inclusion Criteria:\n\n* Age 18 to 65 years old;\n\n  * BMI\\>25Kg\u002Fm2 or abdominal obesity (i.e. waist circumference\\>90cm for men and\\>85cm for women);\n\n    * eGFR\\\u003C30ml\u002Fmin\u002F1.73m2 or urinary microalbumin≥300mg\u002Fg, eGFR\\\u003C60ml\u002Fmin\u002F1.73m2.\n\nExclusion Criteria:\n\n* Patients who are taking glucocorticoids;\n\n  * Combined with tumors; ③Combined with autoimmune diseases; ④Serum albumin\\\u003C25g\u002FL.","65 Years",{"count":212,"type":21},100,"Establish a cohort of diabetic kidney disease(DKD) patients with intensive weight loss treatment to evaluate the impact of intensive weight loss treatment on the renal prognosis of DKD and construct a prediction model for the improvement of renal outcomes after weight loss.",[215,27],"Bariatric Surgeries","2024-10-24",{"date":218,"type":38},"2024-10-28",{"date":220,"type":38},"2023-10-01",{"date":222,"type":21},"2025-10-30",{"name":224,"class":45},"China-Japan Friendship Hospital",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":186,"sex":17,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100553125","comparative-effectiveness-of-low-extra-corporeal-shock-wave-versus-acetylcholine-iontophoresis-on-type2-diabetic-neuropathy-100553125","NCT06482021","Comparative Effectiveness Of Low Extra-Corporeal Shock Wave Versus Acetylcholine Iontophoresis On Type2 Diabetic Neuropathy","Comparative Effectiveness Of Low Extra-Corporeal Shock Wave Versus Acetylcholine Iontophoresis On Type2 Diabetic Neuropathy: Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients have to be symptomatically stable with type 2 diabetes mellitus complicated with peripheral neuropathy.\n* Optimized pharmacological treatment that will be remained unchanged throughout the study.\n\nExclusion Criteria:\n\n* Implanted cardiac pacemakers.\n* Patients with known skin allergies.\n* Presence of skin inflammations.\n* Peripheral vascular disease.\n* Patients with unstable angina pectoris.\n* Progressive ventricular dysrhythmia.\n* Intermittent claudication.","40 Years","60 Years",{"count":103,"type":21},[236],"NA","In our thesis, we will compare the effectiveness of low-intensity shock wave versus acetylcholine iontophoresis as a possible new therapy for microcirculation changes in type 2 diabetic neuropathy",[27],[240],"Acetylcholine iontophoresis, shockwave","2024-06-25",{"date":243,"type":38},"2024-07-01",{"date":245,"type":21},"2024-07-10",{"date":247,"type":21},"2024-10-01",{"name":249,"class":45},"South Valley University"]